Cytokinetics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Cytokinetics, Inc. (Nasdaq: CYTK) will participate in two upcoming investor conferences: the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 8:10 AM ET, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:30 PM ET. The presentations will feature Fady I. Malik, M.D., Ph.D., and Andrew Callos. Live webcasts will be available on Cytokinetics' website, with replays archived for 90 days. Cytokinetics focuses on developing treatments for muscle performance-related diseases.

SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the company is scheduled to participate in the following investor conferences:

• Morgan Stanley 20th Annual Global Healthcare Conference on Monday, September 12, 2022 at 8:10 AM ET in a fireside chat with Fady I. Malik, M.D., Ph.D., Executive Vice President of Research and Development, and Andrew Callos, Chief Commercial Officer, at the Sheraton New York.
• H.C. Wainwright 24th Annual Global Investment Conference on Tuesday, September 13, 2022 at 12:30 PM ET in a presentation with Fady I. Malik, M.D., Ph.D., Executive Vice President of Research and Development, at the Lotte New York Palace Hotel.

Interested parties may access the live webcast of these presentations by visiting the Investors & Media section of the Cytokinetics website at www.cytokinetics.com. The webcast replay will be archived on the Presentations page within the Investors & Media section of Cytokinetics' website for 90 days following the conclusion of the event.

About Cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Cytokinetics is readying for the potential commercialization of omecamtiv mecarbil, its cardiac muscle activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in patients with heart failure. Cytokinetics is also developing aficamten, a next-generation cardiac myosin inhibitor, currently the subject of SEQUOIA-HCM, the Phase 3 clinical trial of aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM). Aficamten is also being evaluated in non-obstructive HCM in Cohort 4 of the Phase 2 clinical trial, REDWOOD-HCM. Cytokinetics is also developing reldesemtiv, an investigational fast skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with amyotrophic lateral sclerosis (ALS). Cytokinetics continues its over 20-year history of pioneering innovation in muscle biology and related pharmacology focused to diseases of muscle dysfunction and conditions of muscle weakness.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics' and its partners' research and development activities of Cytokinetics’ product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics' business outlined in Cytokinetics' filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics' actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Communications, Investor Relations
(650) 624-3071

FAQ

What conferences is Cytokinetics scheduled to attend in September 2022?

Cytokinetics is scheduled to attend the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, and the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022.

Who will represent Cytokinetics at the upcoming investor conferences?

Fady I. Malik, M.D., Ph.D., Executive VP of Research and Development, and Andrew Callos, Chief Commercial Officer, will represent Cytokinetics at the conferences.

How can I access Cytokinetics' conference presentations?

You can access Cytokinetics' conference presentations via live webcast on their website, with replays archived for 90 days after each event.

What is Cytokinetics' focus in biopharmaceutical development?

Cytokinetics focuses on discovering and developing treatments for conditions where muscle performance is compromised, including cardiac and skeletal muscle disorders.

What recent clinical trial results is Cytokinetics preparing for commercialization?

Cytokinetics is preparing for the potential commercialization of omecamtiv mecarbil, following positive results from the GALACTIC-HF Phase 3 clinical trial in patients with heart failure.